Cargando…
Budget impact analysis of breast cancer medications: a systematic review
BACKGROUND: Breast cancer (BC) is the most common cancer globally among women, with 2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both. BC subtype guides the standard systemic therapy administered, which consists of endocrine therapy for all HR + tumors, trastuzum...
Autores principales: | Mohammadnezhad, Ghader, Sattarpour, Melika, Moradi, Najmeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801587/ https://www.ncbi.nlm.nih.gov/pubmed/36581921 http://dx.doi.org/10.1186/s40545-022-00493-1 |
Ejemplares similares
-
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
por: Mohammadnezhad, Ghader, et al.
Publicado: (2022) -
A systematic review of the budget impact analyses for antitumor drugs of lung cancer
por: Han, Lu, et al.
Publicado: (2020) -
Systematic review of women's knowledge, attitude, and practice towards breast cancer
por: Meshkani, Zahra, et al.
Publicado: (2022) -
Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations
por: Meshkani, Zahra, et al.
Publicado: (2021) -
Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review
por: Luo, Zejun, et al.
Publicado: (2021)